Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psori...

por Coates, Laura C, Kishimoto, Mitsumasa, Gottlieb, Alice, Shuler, Catherine L, Lin, Chen-Yen, Lee, Chin Hyok, Mease, Philip J
Publicado 2017

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

por Coates, Laura C., Orbai, Ana-Maria, Morita, Akimichi, Benichou, Olivier, Kerr, Lisa, Adams, David H., Shuler, Catherine L., Birt, Julie, Helliwell, Philip S.
Publicado 2018

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies

por Kavanaugh, Arthur, Gottlieb, Alice, Morita, Akimichi, Merola, Joseph F, Lin, Chen-Yen, Birt, Julie, Shuler, Catherine L, Hufford, Matthew M, Thaçi, Diamant
Publicado 2019

Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience

por Callis Duffin, Kristina, Bukhalo, Michael, Bobonich, Margaret A, Shrom, David, Zhao, Fangyi, Kershner, James R, Gill, Anne, Pangallo, Beth, Shuler, Catherine L, Bagel, Jerry
Publicado 2016

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

por Gottlieb, Alice B, Strand, Vibeke, Kishimoto, Mitsumasa, Mease, Philip, Thaçi, Diamant, Birt, Julie, Lee, Chin H, Shuler, Catherine L, Lin, Chen-Yen, Gladman, Dafna D
Publicado 2018

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, doub...

por Mease, Philip J, van der Heijde, Désirée, Ritchlin, Christopher T, Okada, Masato, Cuchacovich, Raquel S, Shuler, Catherine L, Lin, Chen-Yen, Braun, Daniel K, Lee, Chin H, Gladman, Dafna D
Publicado 2017

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

por Chandran, Vinod, van der Heijde, Désirée, Fleischmann, Roy M, Lespessailles, Eric, Helliwell, Philip S, Kameda, Hideto, Burgos-Vargas, Ruben, Erickson, Janelle S, Rathmann, Suchitrita S, Sprabery, Aubrey Trevelin, Birt, Julie A, Shuler, Catherine L, Gallo, Gaia
Publicado 2020